Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cardium Therapeutics and its subsidiary InnerCool Therapies have completed a $5 million commercial credit facility with Life Sciences Capital to support the launch of InnerCool's new product lines for patient temperature modulation and other ongoing product development activities.
Subscribe to our email newsletter
Christopher Reinhard, chairman and CEO of Cardium and InnerCool, said: “Cardium and InnerCool recently announced the launch of the new CoolBlue surface-based patient temperature modulation system and expect to announce the launch of InnerCool’s new RapidBlue endovascular system next quarter. These two next-generation systems are designed to advance InnerCool to the forefront of the emerging field of therapeutic hypothermia by making it the only company positioned to offer leading approaches to temperature modulation both from outside the body for less acute situations, and from inside the body for acute settings.”